Hi Kiwi,

Its interesting!

Stelara targets IL-23 and IL-12.
A different drug, BI 655066, also targets the cytokine IL-23 (only).
Stelara and BI 655066 were compared in a trial.
In the Phase 1 Trial, BI 655066, performed better than Stelara.

"Earlier in March, data from a Phase I trial of BI 655066 were published in the Journal of Allergy and Clinical Immunology. In that trial, more than half of patients on the drug experienced at least a 90 percent improvement in psoriasis after three months, researchers reported."

BI 655066 has moved on to Phase 2 Trial.

https://www.psoriasis.org/advance/tr...r-than-stelara

It's appearing as though the idea of targeting IL-23 may be very helpful.

People really suffer with Psoriasis.

I've been fortunate to deal with only minimal skin psoriasis. I had started to experience more this year, yet still minimal. I do deal with progressing psoriatic arthritis and my treatment options are very limited due to co-existing medical conditions.

I am usually keeping an eye on the research.

Thanks for your feedback.

Warmly,
DejaVu